Cardiorenal Metabolic Syndrome MRAs and Potassium Binders

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=4hEyR-SIBJI

Drs Nihar Desai, Andrew J. Sauer, and Matthew A. Sparks discuss novel therapies in cardiorenal metabolic syndrome, focusing in on the MRAs and potassium binders. • • Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/.... The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. • • Resources • • The Kidney Failure Risk Equation: Evaluation of Novel Input Variables Including eGFR Estimated Using the CKD-EPI 2021 Equation in 59 Cohorts https://pubmed.ncbi.nlm.nih.gov/36857... • • Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association https://pubmed.ncbi.nlm.nih.gov/37807... • • KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/38490... • • Heart Failure in Patients With Chronic Kidney Disease https://pubmed.ncbi.nlm.nih.gov/37763... • • Lokelma Prescribing Information https://den8dhaj6zs0e.cloudfront.net/... • • Sodium Zirconium Cyclosilicate in Hyperkalemia https://pubmed.ncbi.nlm.nih.gov/25415... • • Veltassa Prescribing Information https://veltassa.com/pi • • Patiromer for the Management of Hyperkalemia in Heart Failure With Reduced Ejection Fraction: The DIAMOND Trial https://pubmed.ncbi.nlm.nih.gov/35900... • • Sodium Zirconium Cyclosilicate in HFrEF and Hyperkalemia: REALIZE-K Design and Baseline Characteristics https://pubmed.ncbi.nlm.nih.gov/38878... • • Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes https://pubmed.ncbi.nlm.nih.gov/33264... • • Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial https://pubmed.ncbi.nlm.nih.gov/34775... • • Press Release: First Patient Enrolled in CARE-HK in HF to Evaluate Role of Veltassa® (Patiromer) in Enabling RAASi Treatment https://newsroom.csl.com/2021-04-28-F... • • Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry https://pubmed.ncbi.nlm.nih.gov/30025... • • Finerenone in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: Rationale and Design of the FINEARTS-HF Trial https://pubmed.ncbi.nlm.nih.gov/38742... • • Additional Studies With Finerenone Across a Wide Range of Heart Failure Patients Initiated https://www.bayer.com/media/en-us/add... • • Treatment Effects of Empagliflozin in Hospitalized Heart Failure Patients Across the Range of Left Ventricular Ejection Fraction — Results From the EMPULSE Trial https://pubmed.ncbi.nlm.nih.gov/38572... • • Safety, Tolerability and Efficacy of Up-Titration of Guideline-Directed Medical Therapies for Acute Heart Failure (STRONG-HF): A Multinational, Open-Label, Randomised, Trial https://pubmed.ncbi.nlm.nih.gov/36356... • • Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs https://pubmed.ncbi.nlm.nih.gov/36328...

#############################

New on site